| Supplementary Protection Certificate (SPC) Summary | |||||||||||||||
| SPC No. | 2015/017 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date of filing | 16/03/2015 | ||||||||||||||
| Notification of Application Published | 08/04/2015 | ||||||||||||||
| Status | Granted | ||||||||||||||
| Notification of Grant Published | 23/09/2015 | ||||||||||||||
| Date of Expiry of SPC | 08/04/2026 | ||||||||||||||
| Applicant |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Binger Strasse 173 55216 Ingelheim am Rhein GERMANY |
||||||||||||||
| Patent Number | 1224170 | ||||||||||||||
| Title of Invention | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | ||||||||||||||
| Date of Expiry of Patent | 08/10/2020 | ||||||||||||||
| Product Type | Medicinal Product | ||||||||||||||
| Product Identity | Vargatef - nintedanib, the tautomers and the physiologically acceptable salts thereof | Market Authorisation | Ireland | European Union | |||||||||||
| Authorisation No | EU/1/14/954/001 - 004 | EU/1/14/954/001 - 004 | |||||||||||||
| Authorisation Date | 21/11/2014 | 21/11/2014 | |||||||||||||
| Identity of Product Authorised | Vargatef - nintedanib | Vargatef - nintedanib | |||||||||||||
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||||||||||||||
| Renewal Fees |
|
||||||||||||||
| 29/09/2023 | Application for an extension of the duration of Supplementary Protection Certificate No. 2015/017 filed on 28/09/2023. | ||||||||||||||
| 09/06/2025 | Application for an extension of the duration of Supplementary Protection Certificate No. 2015/017 granted on 09/06/2025. Expiry date of SPC changed from 08/10/2025 to 08/04/2026. | ||||||||||||||
| 18/06/2025 | Notification of a waiver received on 27 May 2025 in accordance with Article 5(2)(b) of Regulation (EC) No 469/2009 (as amended by Regulation (EU) 2019/933) concerning the Irish Supplementary Protection Certificate 2015/017. | ||||||||||||||